Management of Vulvar Cancer

Dear Colleagues,

Vulvar cancer (VC) is a rare malignancy, accounting for an estimated 5.6% of all gynecologic malignancies and 3.7% of gynecologic cancer deaths. Ninety percent of primary VCs are squamous cell carcinoma (SCC), while other rare histologies include Bartholin gland adenocarcinoma, melanoma, extra-mammary Paget’s disease, verrucous carcinoma, basal cell carcinoma, and sarcoma. Risk factors for the development of vulvar neoplasia include old age, human papillomavirus infection, cigarette smoking, inflammatory conditions, and immunodeficiency.A surgical and reconstructive treatment approach has so far been a cornerstone of the different strategies at both initial and advanced stages. Significant advances have been made over time in pre-operative work-up and surgical planning, turning from 'en-bloc' surgery, which is burdened by the highest morbidity, to more conservative approaches without compromising oncologic safety.Moreover, the integration with other treatments, such as radio–chemotherapy, brachytherapy, or electrochemotherapy, has improved overall clinical outcomes, allowing for additional opportunity even in cases unsuitable for upfront surgery.The benefits of personalized approaches by multidisciplinary integration are also clearly emerging, with the need to address cases to dedicated reference centers. Sample collection and data sharing should be encouraged to achieve a specific molecular profile and to design new translational pathways.This Special Issue will provide new insights into the experimental, translational, and clinical field of VC.We welcome the submission of original research articles and reviews on these relevant topics for each major vulvar malignancy, their respective prognoses, and current management recommendations.

Dr. Giacomo Corrado
Prof. Giorgia Garganese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.